View
3
Download
0
Category
Preview:
Citation preview
http://www.herbridge.com · 1Asiaceutical Insights / 10th Issue 2017
Quarterly siaceutical
Building Health Bridge Between Asia and the World 10th Issue nsights
Media
2 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 1Asiaceutical Insights / 10th Issue 2017
2 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
CONTENTS10th Issue 2017
4 Asia Nutrition Industry Newsflashes:
10 China Consumer Spending $29 Billion on Health Food Annually
12 Japan Health Food Markets Classified on the Basis of Functional Claim, the Market Size of Intestinal Tract Regulation and Obesity Prevention and Oral Health are Expanding
14 Market Views for Milk Thistle Extract(Silymarin)2017
SponsorCo-Sponsor
PublisherChief Consultant
Conference Director
Herbridge Media Co;Ltd
Herbridge Media
Herbridge Media
Zhanglin Liu, David Zhang.
Gloria.Zhang
Address
Telephone
FAX
Website
RM 2309, 23/F, HO KING COMM CTR, 2-16 FAYUEN ST,MONGKOK KOWLOON, HONG KONG00852-30522777 00852-27810061gloria@herbridge.com herbridge@vip.163.comwww.herbridge.com
Guiding natural ingredients industry development
Transmitting China Nutrition Market News
Subscribe Asiaceutical Insights e-Magazine
Asiaceutical Insights is sending Monthly by Herbridge
Media Subscription information
Your company:
Your department:
Your title:
Your E-Mail:
Recommending your colleagues or other friends mail:
Prescribe Asiaceutical Insights E-News, Please mail to gloria@herbridge.com, Asiaceutical Insights is available to all the nutrition industry players.
Asiaceutical Insights
http://www.herbridge.com · 3Asiaceutical Insights / 10th Issue 2017
16 Prebiotics inulin, creating a new world for snacks
19 Luo Han Guo(Monk Fruit) Extract—— Hypoglycemic Star
22 What are the challenges faced by FSMPs (Food for Special Medical Purpose) in China?
27Yunnan Aims to Create a “Healthcare Products Kingdom”
28Beverage Companies Step on the “Healthy” Route, Wahaha & Master Kong Taking the Lead
30China Pharmaceutical Enterprises Transform to Healthcare Products Manufacturing
31Jingdong has once again bagged two Australian brands: targeting health care and meat products!
32Mannatech established cross-border E-commerce platform in China
32BigStylist, an India beauty care O2O platform, plans to collect $400 million through financing
33VIPSHOP holds hands with Blackmores
33Marriage of Global and Jamieson promotes a younger health care market?
34Beijing Consumers Association: cross-border E-commerce has become a severely-afflicted area for sales of counterfeit health care food products
35Jamieson health care products settled in Vipshop
36CFDA released Detailed Regulations for Health Food Products Registration
4 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Asia Nutrition Industry Newsflashes:
Shandong Dong-E E-Jiao Healthcare Operating Revenue Reached ¥700 Million
Dong-E E-Jiao (000423) released its performance as of
2016. During the reporting period, Dong-E E-Jiao’s gross
revenue increased by 15.92% on year-on-year basis, realizing
about ¥6,317 million; and its net profit saw a year-on-year
growth of 14%, reaching ¥1,852 million. Its subsidiary
Shandong Dong-E E-Jiao Healthcare Products Co., Ltd.,
mainly engaged in manufacturing and marketing of healthcare
products, reached ¥714 million of operating revenue in 2016.
4 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 5Asiaceutical Insights / 10th Issue 2017
CR Pharmaceutical Launch Healthcare Products in 2017
In 2016, CR Pharmaceutical realized ¥8,981 million of
operating revenue with a year-on-year growth of 13.69%; whereas
the net profit decreased by 4.11% on year-on-year basis, realizing
¥1,197 million. Among which, the operating revenue of the self-
diagnosis field relying mainly on OTC and business relevant to
comprehensive health reached ¥4,689 million with a year-on-year
growth of 7.06%. One of the key measures that the company plans
to take in 2017 is to make vigorous efforts in the comprehensive
health industry, including developing the healthy products extended
on the basis of the core therapy area such as ginger tea with brown
sugar, peppermint candy, etc., the mainstream dietary nutritious
supplements in the healthcare product market such as vitamins
and minerals, etc., as well as tonic herbal medicine and the herbal
medicine can be taken as both a food and medicine etc. based on
traditional medicinal materials.
JZJT Pharmaceutical’s Revenue from Healthcare Products Decreased by 20%
In 2016, JZJT (600750)’s operating revenue decreased
by 39.87%, realizing ¥1,562 million; whereas its net profit
reached ¥380 million with a year-on-year growth of 3.47%.
Regardless of the impact brought by the external transfer
of Jiangxi Jointown Pharmaceutical in 2015, the operating
revenue decreased by 12.09% on year-on-year basis.
Among which, the area of “healthcare food and others”
relying mainly on Chuenu series and Shenlingcao Oral Liquid
etc. realized annual operating revenue of ¥240 million which
decreased by 23.33% year-on-year.
Yiling Pharm Realized ¥3,800 Million of Annual Revenue in 2016
Yil ing Pharmaceut ica l
(002603) published its annual
report of 2016. In 2016, the
company realized an operating
revenue of ¥3,820 million with
a year-on-year growth of 19.95%; and its net profit saw a year-
on-year growth of 25.91%, realizing ¥542 million.
The company showed that, it has developed a series
of healthcare food and nutritious health food aiming at the
medicinal and edible plant nutrition area, children nutrition
area and sub-health area, providing the rich product reserve for
the company’s sustainable development in the future.
Shanghai Pharmaceuticals Got ¥120.8 Billion Revenue in 2016
Shanghai Pharmaceuticals
(601607.SH; 2607.HK) released
its performance report of 2016. In
2016, Shanghai Pharmaceuticals
realized an operating revenue of
¥120,765 million with a year-on-year growth of 14.45%; and its
net profit saw a year-on-year growth of 11.10%, reaching ¥3,196
million. After entering the comprehensive health area through
international M&A, the company has completed the privatization
project of the Australian listed company, Vitaco Holdings Limited
(“Vitaco”), and acquired 60% stock rights of Vitaco at the cost
of ¥930 million in cash. The acquisition was a key measure
for Shanghai Pharmaceuticals to enter the comprehensive
health industry, which not only brought the company the future
revenue from the industry development, but also promoted the
international development of the company.
http://www.herbridge.com · 5Asiaceutical Insights / 10th Issue 2017
6 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights6 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Harbin High Tech Realized ¥6 million from Healthcare Products
Annual performance of Harbin High Tech
(Group) Co., Ltd (600095) in 2016: the company
showed a 3.92% year-on-year decline in operating
revenue which realized ¥254 million; its net profit
reached ¥15,377,300 with a year-on-year growth
of 5.49%. In the area of soybean deep processing,
healthcare products realized ¥5.99 million of revenue
which accounted for 2.36% of the company’s gross
operating revenue, and gained ¥710,000 of net profit.
In 2016, for the sake of integration of resources and
complementary of advantages, Harbin High Tech
integrated the business of its soybean food subsidiary
and nourishment subsidiary. After the integration, in
the area of soybean deep processing, the company,
based on producing existing isolated soy protein
products, developed a series terminal products taking
isolated soy protein as the raw materials and “Su Mei
Liang” (respectively means simple, beautiful and
pretty) as the brand.
CR Pharm Operating Revenue from Nutr i t ional Heal thcare Products Increased by 40%
2016 annual performance of CR Pharmaceutical
(03320): the company gained HKD156,705 million of
revenue with a year-on-year growth of 6.9%; and it saw
a 1% year-on-year decrease in net profit which realized
HKD2,821 million. Among which, the revenue from
nutritional healthcare products reached HKD524 million
with a year-on-year growth of 37.1%, mainly due to the
increasing market requirement of nutritional healthcare
products and the enhancement of terminal promotion.
North China Pharmaceutical Gained ¥8 Billion of Operating Revenue
North China Pharmaceutical (600812)
released its 2016 annual performance: the
company saw a year-on-year growth of
2.28% in operating revenue, realizing ¥
8,082 million; and gained a net profit of
¥54 million which decreased by 13.42% on year-on-year basis. Among
which, the operating revenue from vitamin and nutritional healthcare
products saw a year-on-year decline of 13.54%, realized ¥229 million.
The subsidiaries Hebei Welcome Pharmaceutical Co., Ltd. and North
China Pharmaceutical Victor Co., Ltd. started to remove and halted the
production in 2015 as required by the government, thus the company’s
revenue from vitamin decreased greatly; the general pharmaceutical
factory started to remove and halted the partial production as required by
the government in 2016, giving rise to the sharp decrease in the revenue
from chemical raw medicine and nutritional healthcare products.
Baiyun Mountain Launch Probiotic Products for Children
2016 annual performance of Baiyun
Mountain (600332): the company realized
¥20,036 million of operating revenue with
a year-on-year growth of 4.76%; and the
net profit decreased by 15.97% on year-
on-year basis, realizing ¥1,508 million. The company possesses four
business areas, among which the area of comprehensive health is mainly
engaged in production, R&D and marketing of drink, food, healthcare
product, cosmeceutical and other products and the main products include
Wanglaoji Herbal Tea, ganoderma lucidum spore oil capsule, lozenge,
turtle jelly, etc. In 2016, its business of comprehensive health achieved ¥
7769 million of operating revenue with a year-on-year growth of 0.01%.
On March 12, Wanglaoji Pharmaceutical announced that it would conduct a
strategic cooperation with DuPont USA in the area of probiotics in terms of
technology, supply chain, market, etc., including launching “Three Dolls”
active probiotic products for children which were divided into two series:
products for children aged from 0-3 and from 3-12.
http://www.herbridge.com · 7Asiaceutical Insights / 10th Issue 2017
Kingdomway Terminated the Acquisition of Shenzhen Youkeshu
Previously, Kingdomway announced
that its company shares were suspended due
to planning of the major issue, namely the
acquisition of 100% stock share of Youkeshu,
the enterprise listed in the New OTC (Over
the Counter) Market. On March 12, the
company received the letter of terminating the
transaction signed by the actual controller
Xiao Siqing from Youkeshu, showing
that Xiao Siqing decided to unilaterally
and irrevocably terminate the transaction.
Therefore, Kingdomway decided to
terminate the planning of this major issue
and not to plan for the acquisition of assets
within one month.
Infinitus Hired Winner of Nobel Prize as Science Consultant, Paying Much Attention to Herbal Medicine
activities, such as anti-infection, anti-
tumor, anti-inflammation, anti-aging, etc.
Prof. Jules A. Hoffmann was once
elected as a member of academy of
sciences of several countries such as
America, France, Germany, Russia, etc.,
and he discovered Toll-like receptors
where are of vital importance to innate
immunization. This revolutionary
discovery provided a basis for the
understanding of the innate immunization
activating the adaptive immunization
and found a new path for the prevention
and treatment of major diseases relevant
to immunization. Hence, Prof. Jules A.
Hoffmann was awarded the 2011 Nobel
Prize in Physiology or Medicine.
The team led by Prof. Jules A.
Hoffmann is subordinate to the supreme
scientific research institute of France –
French Academy of Science. The team
is a strong performer in the research
of the innate immune system, mainly
studying the innate immune resistance
and recovery mechanism during the
process of fungal and virus infection
and paying attention to the study of
transformation from model organism to
human body and its application.
Prof. Jules A. Hoffmann found
in studies that, China has a history of
Chinese herbal medicine for thousands
of years, and the fast development
of the modern immunology theory
and t e chno logy i n r ecen t yea r s
also provides a technological and
methodological reference for the
modern immunopharmacology research
of Chinese herbal medicine. Serving
as an eminent expert of the research
area of immunization, Prof. Jules A.
Hoffmann showed to the reporter:
nowadays, Chinese herbal medicine’s
effect is attracting increasing attention,
and the important role of herbal
medicine in regulating the immune
system has drawn the interests of the
global academic circles.
On March 6, the French winner
of 2011 Nobel Prize in Physiology
or Medicine Prof. Jules A. Hoffmann
received the invitation from Infinitus
(Ch ina ) Co . , L td . and began to
serve as a Science Consultant of the
company. Both parties will promote the
transformation of basic immunological
research into application of health
products based on Chinese herbal
medicine, so as to provide consumers
with health products with better effects.
Increasing studies show that a
lot of Chinese herbal medicine and its
chemical components have distinctive
immunoregulatory activity. For example,
polysaccharide extracted from Chinese
herbal medicine can activate through
TLR the important immune cells from
the innate immune system – dendritic cell
and macrophage, and thus activate the
innate immune system of the organism
and regulate the adaptive immune
system, showing multiple biological
French Winner of Nobel Prize in Physiology or MedicineProfessor Jules A. Hoffmann
8 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 9Asiaceutical Insights / 10th Issue 2017
10 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
China Consumer Spending $29 Billion on Health Food Annually
10 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 11Asiaceutical Insights / 10th Issue 2017
Published by Beijing Daily: the
2017 Top Health Industry Trends and
Issues released by PWC a few days ago
showed that, in the comprehensive health
and relevant industries, the China market
is a Blue Ocean Market, which is still
small in comparison to the global market
size of USD1,490 billion; however, the
China market has been increasing rapidly
at annual double-digit growth in recent
years, and the market size is estimated to
reach USD80 billion in 2020.
N u t r i o l o g y i s b e c o m i n g
increasingly important in the field of
comprehensive industry. At present,
health food consumption of the China
market has reached RMB29 billion
annually. Data further shows that, China
consumers are willing to pay 30% of
product premium or even higher for
healthier and superior food. However,
merely claiming that the product is a
“healthy food” cannot attract consumers,
and China consumers are more likely to
trust manufacturers’ qualification and
the products of big brands.
O n t h e o t h e r h a n d , m a n y
problems exist in the t radi t ional
health-seeking and medical payment
process of domestic hospitals, such as
the complicated payment links, slow
payment speed, etc. In recent years,
people have been exploring optimum
proposals for the medical payment
system, and the new modes of payment
represented by mobi le payment ,
hospital patient ID card and social
security IC card have emerged as the
times require. But the appearance of
these new modes of payment is also
accompanied by several problems. For
example, lacking the overall planning
and coordination mechanism of the
cross-hospital payment system, “one
card for one hospital” brought patients
inconvenience when seeking medical
advice; the coexistence of multiple
payment modes in one hospital caused
pressure for information integration
and system coordination; besides, the
independent construction of the third-
party payment platform in cooperation
with the hospitals lacks of unified
management, showing security risks.
12 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Japan Health Food Markets Classified on the Basis of
Functional Claim, the Market Size of Intestinal Tract Regulation and Obesity Prevention and Oral Health are Expanding
Japan health industry professional media ‘Health Industry
Magazine’ released investigation of Japan health food markets
classified in accordance with raw materials, and released the data of
the size of the top 15 markets with different functional claims, such as
“regulation of intestinal tract · intestinal environment”, etc.
The market of ‘regulation of intestinal tract · intestinal
environment’ ranking first by size increased greatly in comparison
to the last year, reaching JPY550 billion. The market of ‘obesity
prevention · losing weight’, ‘improvement of looks · skin care’
and ‘decayed tooth · oral cavity’ also saw a rapid growth.
However, the market of ‘joint · preventing inflammation’ and
‘vigor · nourishing the body’ didn’t see an obvious growth.
In 2015, the market of ‘regulation of intestinal tract
· intestinal environment’, which ranked first in the market
classified on the basis of functional claim, reached JPY550
billion. What promoted the market development were the relevant
products (including processed food) of lactic acid bacteria and
Bifidobacterium. Especially, the market of lactic acid bacteria
has formed the size of JPY510 billion. Consumers’ awareness of
intestinal health has improved and lactic acid bacteria has become
easily bought and eaten, and its relevant commodities have also
become the driving force of the entire market of health food.
The market ranked second was ‘overall body balance’,
including green juice, plant fermentation extract (enzyme),
nucleic acid, vitamin, healthy vinegar, etc. Benefiting from the
expansion of the tourists’ “explosive shopping” market since
2014, the market of ‘body balance’ has maintained a rapid growth
and reached JPY317 billion.
Both the market of ‘obesity prevention· losing weight’,
which ranked third with JPY160 billion, and ‘improvement of
looks · skin care’, which ranked fourth with JPY146 billion, have
seen a remarkable growth compared to the last year.
12 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 13Asiaceutical Insights / 10th Issue 2017
No.1 ‘regulation of intestinal tract · intestinal environment’
Market size: JPY550 billion
Principal raw materials: lactic acid bacteria, Bifidobacterium, etc.
No.2 ‘overall body balance’
Market size: JPY317 billion
Principal raw materials: green juice, enzymes, vitamin, black
vinegar, nucleic acid, etc.
No.3 ‘obesity prevention · losing weight’
Market size: JPY160 billion
Principal raw materials: meal substitutes, herb, partial amino
acid, etc.
No.4 ‘improvement of looks · skin care’
Market size: JPY146 billion
Principal raw materials: collagen, placenta extract, hyaluronic
acid, royal jelly, etc.
No.5 ‘joint ·preventing inflammation’
Market size: JPY76 billion
Principal raw materials: glucosamine, chondroitin sulfate, MSM,
type-II collagen, proteoglycan, etc.
No.6 ‘improvement of blood flow’
Market size: JPY60 billion
Principal raw materials: ginger, onion, natto, earthworm kinase,
etc.
No.7 ‘eye health’
Market size: JPY59 billion
Principal raw materials: blueberry, lutein, etc.
The market of ‘decayed tooth · oral cavity’ also increased greatly, ranking 13th with JPY35 billion. For the sake of preventing
consumers’ oral problems, there is increasing food favorable for oral health in the market. Besides the special protective food, the
requirement for tablet products based on plant extract is also increasing, which is inseparable from the formative market education of the
huge impact the oral health has on people’s physical health.
However, the market of ‘joint · preventing inflammation’ and ‘vigor · nourishing the body’ didn’t see an obvious growth,
maintaining basically the same as that of the last year.
No.8 ‘vigor · nourishing the body’
Market size: JPY50 billion
Principal raw materials: Lepidium meyenii, allicin, soft-shelled
turtle, etc.
No. 9 ‘diabetes prevention · blood glucose level’
Market size: JPY49.5 billion
Principal raw materials: Salacia chinensis, guava leaf, resistant
dextrin, etc.
No.10 ‘immunization’
Market size: JPY47 billion
Principal raw materials: mushrooms, bee glue, brown seaweed, etc.
No.11 ‘exercise · muscular strength’
Market size: JPY41 billion
Principal raw materials: albumen powder, partial amino acid
No.12 ‘liver function’
Market size: JPY40 billion
Principal raw materials: turmeric, ornithine, liver of pig, etc.
No.13 ‘decayed tooth · oral health’
Market size: JPY35 billion
Principal raw materials: xylitol, etc.
No.14 ‘brain health · mental health · sleep’
Market size: JPY26 billion
Principal raw materials: ginkgo leaf, PS, GABA, theanine, etc,
No.15 ‘blood pressure’
Market size: JPY22 billion
Principal raw materials: oligopeptide, etc.
14 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Milk Thistle, which was launched
on the mainland since 90’s in last
centuryhas been around for 40 years. It
was introduced to the area of Hanzhong
in Shaanxi, Weinan and Panjin, liaoning
province by professor Huang Shouxing
worked in Xi’an Arboretum, and
succeeded in planting.
The processing of Milk thistle
extract is contacted by “Panjin Milk
Thistle Synthesizes Plant ”, “Jiangsu
Apocynum Factory ” and “Shaanxi Hua
County Shaohua Mountain Refinery
Factory ”, and at that time, the plant
area of Milk thistle is small, the farming
and harvesting are all artificial, planting
technology is not mature and the produce
capacity of the manufacturer is small,
less specifications of extract, also the
quality needed to be raised.
With 40 years effort, manufacturers
do a lot of work on the hi-tech innovation
and R&D, in the new situation of the
global promotion, the demand of Milk
thistle extract has greatly increased.
The milk thistle extract manufacturers
increased to at least 30 or more, most
of them distributed in Panjin, liaoning
province and Dongtai, jiangsu province.
The planting base of Milk Thistle has
transferred to Panjin area, Suihua area in
Hei Longjiang provice, and Hai la’er area
in Nei Menggu province. The planting
field management and harvesting has
realized the mechanization in this
period which improved the quality of
Market Views for Milk Thistle Extract(Silymarin)2017Wu Changjun, LIVERD PHARMA CO., LTD.
http://www.herbridge.com · 15Asiaceutical Insights / 10th Issue 2017
raw material and reduced the cost, thus,
the raw material can satisfy the need of
marketing and get relatively stable price.
The total quantity of raw material has
reached 35000 tons in 2016, the cultivated
area of 2017 will reach 50000 to 60000
Mu, estimated yield will be 40000 tons, the
quantity can totally meet market demand,
the price of the milk thistle extract will be
stabilized. If there is no natural
disaster in the plant base, the
price will be no big fluctuation
over two to three years.
Main Specifications for Milk Thistle Extract/Silymarin
According to the different
extract solvents used, Milk
thistle extract fall into three
classes: Silymarin extracted
by Acetone, Silymarin extracted by
Ethyl Acetate and Silymarin extracted by
Ethanol. Ethyl Acetate and Acetate are
the traditional extract solvents used in the
process of milk thistle extract producing.
Since 2008, Ethanol has applied to milk
thistle extracting, and technical progress
solved the problem of low content if use
ethanol to do extract, and till now, this
product has been widely used because of
its non-toxic and no side effects.
According to the standard, Silymarin
got from different extract solvents has
different contents and can meet different
pharmacopoeia requirements, such as EP,
USP, DAB and each specification with
different extract solvents running into
more than 30 contents.
Separation and purification of Silybin
As the new products continuously
developed, the market of Silybin is
increasing, and the contents can be done
from 75% to 99%.
Silymarin water soluble and Silybin
water soluble, can be absorbed by human
body fully and usually work better.
Nowadays, silymairn water soluble
series products have been developed and
launched, and has been widely used.
Price for Milk Thistle extractsThe price of raw material is the
main determinant for the milk thistle
extract, 2014-2016, the price of milk
thistle seeds has down from CNY 12000
- 13000 per Ton to CNY8500 - 9500 per
ton. The main reasons for falling prices
as follows:
The improvement of farming
techniques boosts yields and makes
lower cost.
The ac r eage i nc r ea sed , and
excessive production.
Development of down stream products
They basically separate into two
types, one is Drug for protecting liver,
and the other is health care products.
Develop in increments: Health-care
food and health beverage and so on.
Future market trends predicted2014-2016, the global demand of
Milk thistle extract is around 1000 Tons,
thereinto, in china, the domestic demand
is around 50 Tons. Within the next five
years, this demond will be growing by
about 10% to 15% annually. The price
of Silymarin will be in the abyss from
2017 to 2018, stability, has no lurches.
The price of raw material will
hover from CNY 8000 to
10000 per ton.
Application for Milk Thistle Extract
Milk Thistle Extract
play a role in protecting liver,
antioxidant properties and
anti fibrosis. It can protect
the liver cell from toxicant
substance abuse, especially
for ethanol and environmental pollutants
(Pesticides,Heavy Metals and so on);
Silymarin has the Powerful antioxidant
function to protect the liver cells from
free radical damage, and which of
function far exceeds VE; Silymarin
can promote protein synthesis, speed
up the new liver cells of manufacturing
or promote the injured liver cells of
self-repair. So, Silymarin is also be
named of “the Natural liver-protection
product”. Silymarin can resist radiation
and aging. In addition, Silymarin has
the abundant nutrition, for example: 15-
19% plant protein, 22-26% grease, 35%
dietary fiber and many Vitamin, mineral
substance. It is 100% plant extract with
no side or toxic effects, many new
products in the field of Medicine, Health
Products, Cosmetics and food have
been developed, broad prospects for
development.
16 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Prebiotics inulin, creating a new world for snacks
For most consumers, probiotics is no longer a strange industry term,
and people’s awareness of the health benefits of probiotics is also constantly
improving. When it comes to the function of probiotics, the first thought
of most people is “intestinal health”, which has already been verified by
scientific experiments and researches. In fact, the function of probiotics is not
that simple, and its biggest role is to affect the balance of intestinal flora, the
imbalance of intestinal flora will induce a series of diseases, such as intestinal
disease (constipation, gastroenteritis, and diarrhea), immune health, diabetes,
angiocardiopathy, cognitive health, metabolic disease (adiposity), etc.
The reasons for the imbalance of intestinal flora are complex, including
lifestyle, eating habits, drugs (especially antibiotics) and age, etc., and how to
16 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
maintain the balance of intestinal flora has
become people’s focus of attention. As the
high-quality “food”, when people supplement
active flora, they pay more attention to the
intake of prebiotics. Prebiotics is not only
the food for intestinal probiotics, but also has
many physiological functions, such as increase
the original intestinal probiotics and activate
intestinal motivity, so people should pay
attention to the rational intake of prebiotics in
the daily diet.
http://www.herbridge.com · 17Asiaceutical Insights / 10th Issue 2017
Prebiotics inulin, creating a new world for snacks
active materials, and it is easily added
into dairy products, food and beverage
products without affecting the taste of
products, and the compound annual rate
of growth of this kind of product will
be the highest in the future. Let’s take
Chinese dairy products as example, the
products from milk powder (excluding
infants) to yoghourt, cheese, and ice
cream more or less are added with inulin,
the reason is that inulin has excellent
solubility, and its combination with water
can produce a fat-like taste and greatly
reduce the use of fat in products. The
most important is that inulin can improve
the absorption and utilization of nutrients
in dairy products, especially calcium. In
addition, the ice cream products have
very wide consumer groups, and the
application of inulin gives these products
a new growth point: low sugar and low
fat, and there will be more and more ice
creams containing inulin in the future
market.
Now bakery products are very
popular with the consumers around the
world, this trend also appears in the Asia-
Pacific region. The breakfast with milk
and bread begins to be popular in China,
especially in the big cities with fast pace
of life. Relevant data has shown that the
number of consumed bakery products
per capita per year in China is 92, which
is much lower than Germany’s 731
per capita, the change of lifestyle and
westernization of eating habits promote
the development of bakery products in
China. The application of inulin fiber
can replace the use of some sugars and
fats, and in general, 0.25g of fat inulin
can replace 1g of fat, and also increase
the fluffy texture and taste of bakery
products, especially the bread products.
Low fat and high fiber are the future
trends of bakery products, and the
application of inulin fiber can solve this
problem.
The role of inulin is variable from
dietary fiber to prebiotics and then to
natural sweetener, it has a faint sweet
In the big family of prebiotics,
“inulin” can be the most shining
member, because it has the properties
of dietary fiber and prebiotics. Inulin
belongs to oligosaccharide, it is not
hydrolyzed by gastric acid or absorbed
by small intestine in human body, but
it is directly fermented by the action
of microorganisms in large intestine,
and it has the functions of preventing
constipation, lowering cholesterol,
lowering blood glucose, controlling
appetite, promoting mineral absorption
and improving intestinal health. Recently,
the Research Center of University
of Newcastle in Australia has first
discovered that inulin fiber can relieve
the symptoms of asthma and reduce
inflammation phenomena of respiratory
passage through acting on intestinal
flora, which undoubtedly opens up a new
application area for prebiotics inulin.
Inulin, better matched with snacks
At present, snacks have changed
from the embellishment food in life into
a kind of necessity, and they are rapidly
increasing in the world, for example, the
majority of consumers in the West have
treated snacks as dinner. At the same
time, consumers have more requirements
on snack products, and they show more
interested in healthy, natural, nutritious
snack products, so the emergence of
prebiotics and inulin provides a practical
solution to this demand.
From the perspective of application,
the most widely applied field of inulin
is food & beverage, followed by dietary
supplement and animal feed. The
characteristics of inulin are stable, so
there is no absorption problem of other
18 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
taste, its heat is only half of the sugar,
and it does not cause an increase in
blood sugar. “Reduce sugar” is one of
the trends in food industry, and many
product developers are in the demand
for natural sweetener, inulin fiber
can replace the use of some sugars in
products without affecting the taste
and sensory quality. Meanwhile, two
experiments conducted by researchers
of Oxford Brooks University show that
food containing inulin can reduce blood
glucose response, prevent and reduce
the risk of chronic metabolic disease. In
addition, inulin can also be mixed with
other natural sweeteners, for example,
mixing with sugar stevia leaf can cover
the delayed bitterness.
Inulin, unwilling to be the “minor role”
Transparent Market Research
Market Report shows that inulin market
capacity in 2011 is 204 thousand tons,
market value is 890 million dollars, and
its market capacity is expected to reach
366 thousand tons in 2018, and market
value will reach 1 billion 870 million
dollars, and the compound annual rate of
growth is 11.1%. Inulin can replace sugar
and fat in food, especially the processed
food and functional food, and it has
become the “popular minor role” in food
world.
Trans-boundary is one of the trends,
the inulin unwilling to be the “minor
role” also begins trans-boundary, and
tries to mix and match with a variety
of natural functional ingredients to
maximize its own health advantages,
of course, this shall depends on the
research & development and innovation
of terminal enterprises. At present,
Chongqing Joywin Natural Products Co.,
Ltd has tried to develop the products
with inulin as the “leading role”, hoping
to push it to the position of leading role.
As China's largest production base
for Jerusalem artichoke and inulin,
Chongqing Joywin starts the layout of
big health industry chain with strong
technical advantage and advantage
of comprehensive control on plant
materials, and now it becomes an
excellent raw material manufacturer
of natural products in China, such
as inulin and plant protease, and it is
forming a new pattern covered by the
whole industry chain from raw materials
to terminal. In the future, Chongqing
Joywin will promote the application of
inulin to broader and deeper fields with
its own advantages.
http://www.herbridge.com · 19Asiaceutical Insights / 10th Issue 2017
Luo Han Guo(Monk Fruit) Extract —— Hypoglycemic Star
Monk Fruit, as one of Chinese endemic and first approved by the state,
medicinal & edible protected plants, has over 300 years of history of cultivating
and using as Chinese Traditional Medicine in south of China. With many
functions such as clearing heat, moistening lung,relieving sore throat and relaxing
bowel. The fruit is rich in nutrition and known as "Oriental Magical Fruit". The
secret of sweet taste in Luo Han Guo - is from Mogroside V.,which is a natural
non-sugar sweet substance, its sweetness is 300 times than that of sucrose, no
calories, safe for eating, is an ideal sugar substitute and natural sweeteners.
Since Mogroside V came into the US market,
the products using it as a natural sweetener
showed explosive growth, and it has become a
new hot spot for growth of Food and beverage
industry in USA, with hundreds of billions
dollars of market development space.
In recent years, as the representatives
of the synthetic sweeteners,aspartame and
sucralose has been questioned for their
safety. Although EFSA had reevaluated
the harmfulness of aspartame in 2013,
the conclusion is: “Aspartame is safe for
consumers.”But it seems that consumers
don’t agree with it. With the improvement of
consumers' health consciousness, it has entered
the consumer's vision that Monk Fruit Extract,
which with double properties of healthy and
zero calorie, will definitely be welcomed by
the consumers,and will bring more sweet
feelings to everyone.
Hunan Huacheng Biotech, Inc.
20 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
promote health." Professor Gibb , the co-
leader of the research team also said that
the impact of levying sugar tax will have a
positive impact, particularly for children.
Not long ago, Pepsi announced that
they will carry out the most strict sugar
control plan in history. By 2025, Pepsi's
two-thirds of the calories of 12-ounce-
drinks(about 354 ml) will be controlled in
less than 100 calories. In January of this
year, Pespsi has just launched a high-end
water brand LIFEWTR, and also launched
another 2 new drinks -- "IZZE Fusions"
and "Lemon Lemon" in USA. These 2
new products are aim at healthy, not only
reduce the sugar but also give up using
artificial sweeteners. The main ingredient
is Stevia. It is learned that the R&D Dept.
of Pepsi is is actively exploring and trying
a new generation natural sweetener --
Monk Fruit Extract, which has a better
taste. It’s expected that it will come to the
market in the nearly 2 years.
In February 2017, Starbucks
spokesman also said that Starbucks has
promised this year, they will reduce
sugar content in their drinks by 25%
before 2020. And a type of green sugar
pack (this "natural sweet" sweetener is
a combination of Stevia and Monk Fruit
Extract) has emerged as a new option in
9000 stores of Starbucks in America and
Canada.
In 2017, Nestle announced that the
sugar content of confectionery products
in UK and Ireland will be reduced 10%,
including Kit Kat, Aero, Milkybar and
other hot selling chocolate sugar. While
reducing sugar content in the food
formulations, Nestle is also looking for a
much better “new sugar”. By the end of
2016, Nestle invented a new
type of sugar formula, under the
premise of not changing its taste, its
sugar content can be reduced by 40%
maximum, and it’s expected to be used
in Nestle food in 2018 or so.
As the representatives of the new
generation of zero calorie, pure natural
sweeteners, Stevia Extract and Monk Fruit
Extract are favored by more and more big
companies. It’s learned that during the
period of 2015-2016, American market
has more than 1000 kinds of new products
which have used Monk Fruit Extract.
Nestle and Tesco, as the representatives
of the European big companies are also
actively exploring new product lines.
It’s speculated that Nestle will become a
pioneer and practitioner in promoting the
improvement of EU regulations, and will
become one of the first European food
companies to use Monk Fruit Extract to
reduce sugar!
Monk fruit extract, as a high
sweetness, low calorie, pure natural and
Governments and people gradually
realize that the harm of excessive sugar
intake, so some governments have taken
measures to control the sugar intake. As
per the reports, due to Thai people's sugar
intake ranking in the world, with high
prevalence of obesity and cardiovascular
disease, the medical expenses are
increasing, Thai government decided to
levy sugar tax, and the prices of sugary
drinks will rise by about 20%, i.e. levy
sugar tax on those companies whose
sugary drinks exceed certain standards(6
grams of sugar per 100 ml) to curb the
excessive sugar intake. The retail prices
of soft drinks or fruit drinks and other
drinks will rise about 20% to 25%.
Now, Mexico has also implemented
levying sugar tax to effectively reduce
the sale of sugar-containing beverages.
In the United Kingdom,they also plan to
implement it in April 2018. Philippines,
Malaysia and Indonesia of the Asian
countries are also interested in following-
up it. If Thailand is the first one to levy
sugar tax, it will be the first country to do
so in Asia. Professor Briggs of Oxford
University said that the impact of sugar
tax on people's health, depending on what
measures will be taken by the relevant
enterprises. "The good news is that our
research shows that all the measures may
taken by the companies are helpful to
http://www.herbridge.com · 21Asiaceutical Insights / 10th Issue 2017
healthy sweetener, has been allowed to
be used as food additive by USA FDA
from 2009, the global demands and
the online search frequency are rising
sharply.
(The images is from Google Trend).
The comprehensive influence of
global sugar reduction and clean label
trends have better promoted the wide
use of natural sweeteners like Monk
Fruit Extract and Stevia Extract. Among
which, the global demands of Monk
Fruit Extract is growing at an annual rate
of 5%. According to the Euromonitor
Global Overview Report company’s
prediction, the global yield of Monk
fruit will be more than 300 MT(based
on Mogroside V 50%) in 2017. China
is the largest production and export
country,while 90% of Monk Fruit Extract
will be exported to USA and Japan. The
Innova data shows that around 50%
of their products will contain Stevia
Extract and Monk Fruit Extract in USA.
The Customs Export Data show that
USA imported about 50 million USD of
Monk Fruit Extract in 2014 and about
55 million USD in 2015, with a year-
on-year growth of 10%. In China, the
national standard of Monk Fruit Extract
Mogrosides V 20% (GB1886.77—2016)
has been issued on Aug 31st, 2016 and
has carried out formally on Jan 1st, 2017.
Chinese market will become the huge
cake for Monk Fruit Extract market.
Monk Fruit Extract hasn’t been allowed
to be used as a sweetener or food
additive in Europe, Australia or other
countries, but with the health concept
of natural sweeteners and consumers’
demands for natural health, we believe in
the next few years in these regions and
countries,related laws and regulations on
Monk Fruit Extract will be recognized,
and its market is immeasurable.
With the development of living
standards, organic products are favored
by more and more manufacturers
and consumers, the global 1st and
unique Crganic Certificate for Monk
Fruit Extract has been obtained by
Hunan Huacheng Biotech,Inc(HC) in
2016. Currently, there are still some
manufacturers worrying about the supply
of its raw materials. Monk Fruit was
originally planted in Guilin, Guangxi
in China, the suitable planting areas are
only about 0.3~0.4 million Mu. To this
problem, HC said:“The growth of Monk
Fruit is indeed difficult, but after 5 years’
trial and large-scale planting, HC has
enlarged another 6 million Mu of suitable
areas in 14 districts adjacent to Guilin,
which equivalent to the raw materials
required for similar sweetness for 1500
MT of sugar”.
With the explosive growth of Monk
Fruit Extract consumption, Monk Fruit
Extract has been the new hot spot in the
new type of healthy food and beverage
industry’s growth at home and abroad
with the sharp increase of its consumption.
The domestic production enterprises
are now facing a severe test, although it
possesses an unprecedented opportunity.
Reducing the cost and improving the
quality of Monk Fruit Extract sweeteners
becomes the most important challenge.
Now,most of the main producers are
expanding planting areas,improving
the production efficiency,optimizing
varieties,using biological pesticide,no
pesticide residue to improve and develop
Monk Fruit’s value. They are also
focusing on research and development
of terminal product formulations to
provide customer solutions. Besides,
developing other sweetless ingredients
in Monk Fruit (dietary fiber,pectin,etc.)
is an important trend in future. Sewerage
drainage was reduced by recycling Monk
Fruit residues. Monk Fruit sweetener will
bring a new climax once the European
market open.
22 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
What are the challenges faced by FSMPs (Food for Special Medical Purpose) in China?
In China, the application of FMSPs has been more than 30 years, and
the gross output value of domestic FMSP market increased from RMB
120 million in 2004 to RMB 2 billion in 2015. National Health & Family
Planning Commission of P.R.C. released GB 29922-2013 National Food
Safety Standard: General Rules for FMSPs and other relevant normative
standards. However, the current development of FMSP industry is still
insufficient, especially the lack of systematic research on this industry.
Through the utilization of the framework for industry innovation system, this
paper analyzes the current situation of FMSP development promoted by local
enterprises in China, and the development of local research institutions and
policies, hoping to provide suggestions for FMSP development in China.
Summary of the proportion of Chinese-funded enterprises and foreign-
funded enterprises
Foreign-funded enterprises:
A number of multinational companies, including Nutricia Pharmaceutical
Co. Ltd., SSPC (Sino-Swed Pharmaceutical Corp. Ltd.), Abbott Laboratories,
Nestle Corporation, have monopolized more than 90% in the domestic FMSP
market. Most of the products of these companies are marked with “OTC”,
including a total of 69 domestically registered products, and 19 categories
involved. The products introduced into China are mainly developed around
1980s. In addition, Abbott “full ansul” has been marked as a new standard
FMSP and the pilot sale has started. Both Nutricia and SSPC have large-scale
production bases established in Wuxi, Jiangsu of China, their products are
available for use abroad, yet their R&D departments are not within China.
22 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
http://www.herbridge.com · 23Asiaceutical Insights / 10th Issue 2017
Table 1 Basic situation of foreign FSMP in China
Company name Year of entry Ownership system Main products
SSPC (Sino-Swed Pharmaceutical Corp. Ltd.) 1982 Joint venture Fresubin Energy Fibre, Fresubin, Suppor-tan, Fresubin MCT 750, Fresubin Diabetes
Ajinomoto Pharma Co.,Ltd. 1984 Wholly foreign-owned Elental
Novartis Pharma AG 1996 Joint venture Impaet
Abbott Laboratories 1998 Wholly foreign-owned Jevity, Ensure, Gluerna SR®, Pulmocare
Nutricia Pharmaceutical (Wuxi) Co. Ltd. 2000 Wholly foreign-ownedNutrison Fibre, Peptisorb Liquid/ Powder, Diason®, Nutrison MCT, Nutrison, Neo-
cate
Nestle Corporation - Wholly foreign-owned Nutren,Vivonex
Note: Mark“-”means that the year of entry remains unclear
mainly used in nutriology departments
of various hospitals. At present, due to
the late entry time into industry, most of
domestic enterprises mainly imitate foreign
products, and they share such common
characteristics as small market share, small
proportion of independent intellectual
property rights, lags in technology, small
investment, and lack of brand influence.
However, it is worth noting that some
progresses of new product developments
have been made in some local enterprises
since the promulgation of new national
standards. For example, Compound
Nutrition Suspension and Enteral
Nutritional Suspension newly developed
by Shanghai DAISY FSMP have received
the approval number approved by SFDA.
Domestic enterprises:Domest ic enterprises mainly
comprise Qingdao Haihui Biochemical
Pharmaceutical Co., Ltd, Guangzhou
Liheng Clinical Nutrition Co., Ltd.
and other enterprises, accounting for
about 10% of domestic market. Product
approvals of these enterprises are marked
with “Health care food product” and
Table2 Basic situation of representative enterprises in China
Company Year of establishment Ownership system Main products
Qingdao Haihui Biochemical Pharma-ceutical Co., Ltd. 1958 Limited liability company
(private) Compound Nutrition Suspension
Xi' an LI BANG Clinical Nutrition Co., Ltd. 1999 Company limited Leskon in-house products
Shanghai Richen Nutrition Products Technology Co., Ltd. 1999 Company limited Richen compound nutrient supplement
Zhejiang Hailisheng Biotech 2000 Limited liability company (private)
Homogenized diets/Fish collagen poly phthalocyanine/ Deep-sea fish collagen
powder/Dedicated for hospitals
Guangzhou EnterNutr Bio-Technology Co., Ltd. 2008 Company limited
Enternutr compound protein powder/ Enternutr homodiabet/Semi-Digested/ Enternutr Peptide/Enternutr Homoge-
nate/Enternutr whole/GLN/FIBER/OLIGO/
Guangzhou BOSSD - Enterprises directly under Sanjiu Group
Homogenate diets/ TRENSINE Composite Strengthening Nutrition
Powder
Daisy FMSPCompound 2013 Company limited Vegetable Protein Peptide Composite
Note: Mark“-”means that the year of entry remains unclear
24 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Hubei, Zhejiang, Jiangsu, Shandong and Beijing, and some progresses have been
made. At present, FMSP developments of China are mainly in its early stages. FMSPs
mainly provide nutritional support for patients and closely related with clinical uses.
However, FMSP-related clinical and basic research data in China are inadequate.
More relevant researches are still needed as to whether newly-developed products can
be more suitable for clinical applications and patients in China.
Domestic enterprises in China have also begun to try to cooperate with
scientific research institutions for joint product developments. For example,
Guangzhou Liheng Clinical Nutrition Co., Ltd versus Institute of Sericulture and
Agricultural Products Processing, Guangdong Academy of Agricultural Sciences;
Tianjin Zhongen Technology Co., Ltd versus Institute of Biophysics, Chinese
Academy of Sciences.
Table 3 FMSP-related Research institutions
Location unit (institutions) Research contents
BeijingCFSA (China National Center for Food Safety Risk As-
sessment)Institute of Nutrient Source
Researches on FMSPs standard and management
Beijing Sun Yat-sen Hospital Analysis and development of FMSPs Clinical effect
Guangdong Province SYSUWuhan Tallyho Biological Product Co., Ltd. comparisons of specific FMSPs
Hubei Province Hubei Peptide Material Engineering Technology Research Center
Prospect researches on the application of foodborne peptides in FMSPs
Zhejiang ProvinceBeingmate Baby & Child Food Co., Ltd.
Zhejiang Key Laboratory of Chemical and Biological Processing of Agricultural Products
Domestic and foreign researches on standards for FMSP infant formula foods
Jiangsu Province Wuxi Jiante Pharmaceutical Co., Ltd.Using the flame atomic absorption spectrometry to research on the determination of interference and elimination of potassium and sodium in FMSPs
Shandong Province Baolingbao Biology Co. Ltd.Research Institute of Agricultural Products,
Researches on the application of dietary fiber in FMSPs
Shandong Province Shandong Academy of Agricultural Sciences Current situation of FMSP industry
Analysis of products and research institutions
FMSPs mainly comprise amino acid
pattern, short peptide pattern and intact protein
pattern. There are balanced type and disease
specific type if classified by types, and there
are diabetes type, tumor type, burn type,
liver disease type and kidney disease type
if classified by disease specific types. In the
current domestic market, FMSP products from
foreign-funded enterprises mainly comprise
intact protein type enteral nutrition agents, i.e.
Nutrison Fibre, Nutrison, Supportan, Fresubin
Diabetes and Anso, short peptides and
amino acids types, i.e. Elental, Peptison, and
Peptisorb, and disease specific preparations,
i.e. Fresubin Diabetes, Diason and TP HE
mainly used for people with diabetes. The
product types of domestic enterprises basically
follow that of foreign-funded enterprises.
Currently, FMSP-related researches and
product developments have been conducted by
scientific research institutions in Guangdong,
http://www.herbridge.com · 25Asiaceutical Insights / 10th Issue 2017
Policy environment is closely
related to the development of medical
food industry. Looking back the
developments of FMSP-related policies
in China, we can mainly divide them into
the following three stages.
Stage I (1970-2000): Initial stage
of policy. At this stage, along with the
development of clinical nutrition, there
are some knowledge about the clinical
effect and social value of FMSPs. For
example, there are reports on the clinical
applications of FMSP in Beijing, China
in 1974. In 1980-1990s, the unique
position of nutrition and specialty in
medical health system was clearly
proposed.
Stage II (2002-2009): Stage of
gradual attention: In 2002, Chinese
Medical Association took the initiative
to classify FMSPs, while government
agencies began to gradually clarify
their health insurance policies. In 2006,
the importance of correct nutrition
consumption on health was clearly
proposed in the Action Plan for Chinese
Nutrition Improvement. Moreover,
guidance scheme for systemic parenteral
& enteral nutrition was formulated in
Clinical “Guidance” Series for Systemic
Parenteral & Enteral Nutrition, which
assisted physicians in considering the
adoption of appropriate nutritional
support program and corresponding
operation specification for parenteral
& enteral preparations according to the
patients’ clinical conditions.
During this period, China reflected
certain requirements for technologies and
functions of FMSP, and also pointed out
problems brought about by unmatched
policy packages, which provided the
scientific basis for the adjustment and
perfection of FMSP-related policies.
Stage III (2009-2015): Stage of
policy refinement. The “food” identity
of FMSPs was specified in the new Food
Safety Law. Before that, FMSPs were
managed according to the chemical drug
registration management prescribed in
the State Pharmaceutical Administration
Law, which affected the product
development of FMSPs in China and
also restricted the entry of products from
foreign-funded enterprises.
In order to solve the problems
arising from product developments
and clinical demands, National Health
& Family Planning Commission of
P.R.C. put forward the “2 + 1” standard
management program. State Food &
Drug Administration also released the
Regulatory Measures for the Registration
of FMSPs (trial implementation), so
as to provide institutional guarantee
and technical support for control and
http://www.herbridge.com · 25Asiaceutical Insights / 10th Issue 2017
26 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Secondly, foreign companies dominate the market, and local enterprises
are facing barriers to entry. At present, foreign brands have occupied a dominant
position in the market, while domestic brands account for only about 10% of
the market. More local enterprises want to enter the FMSP industry, but they
have to face with all kinds of difficulties. As a result, the majority of enterprises
hold the attitude of wait-and-see. In particular, new entrants need to re-establish
a production line in conformity with relevant provisions of food production,
and also need for more investments in test and inspection, which means a huge
challenge for domestic enterprises.
Thirdly, at present, the relevant national policies, regulations and standards
are still imperfect, and such links as product
approval and regulation of production and market
are not standardized. Although the newly-released
standards allow consumers to make a major shift
in the understanding of FMSPs, and also define the
distinction between functional foods and health
care products, yet sports food, health food or
functional food are still included under the FMSP
directory of some enterprises, which shows that
many efforts in policy implementation are still
required during the fulfillment and enforcement of
new standards.
In addition, the health-seeking behaviors
among people and the mindset in doctors’
treatment also affect the application of FMSPs. On
one hand, it is still difficult for doctors to accept
products under the name of “food”. On the other
hand, the treatment conception among patients
also tends to be dominated by doctors. i.e. too much
emphasis on drug treatment, with negligence of the role of FMSPs in treatment
and rehabilitation. Moreover, FMSPs can’t be supplemented into the medicare
system, and consumers can’t be reimbursed, which is also an influencing factor.
It is precisely because of the above problems that FMSP developments in
China still lag behind the developed countries in Europe and the U.S.A. In view
of the huge population and the increasing demands for nutrition and health,
FMSPs are sure to have a very good prospect in the future. FMSPs are still in its
initial stage of industrial development in China, and it is required to start from
the perspective of industrial innovation system and make collaborative efforts
in terms of three aspects, i.e. knowledge & technology development, enterprise
& network construction, and policy construction. Only in this way, positive and
further development can be obtained in Chinese FMSP industry.
surveillance over FMSPs, enable the established
regulations to be in conformity with the law,
the realistic demands of regulatory authorities
and manufacturers, fundamental needs for the
quality safety of FMSPs, and clarify registration
conditions, enterprise production capacity,
clinical trials, etc.
Through the retrospective analysis of the
development of Chinese medicine formula
food industry, it can be found that there are
3 c ha l l enges i n t he
development of Chinese
medicine formula food.
First of all, limited
s c i e n t i f i c r e s e a r c h
suppor t and lack of
evidence-based medicine
h a v e r e s t r i c t e d t h e
industry development to
some extents.
F o r e x a m p l e ,
foreign brand products
sold in the market are
compounded by use
o f s ing l e nu t r i en t s ,
resulting in high osmotic
pressure, incompetence
fo r ga s t ro in t e s t i na l
tolerance among Chinese
people and easy occurrence of diarrhea
among patients. On the other hand, domestic
brand products are featured with low pre-
digestibility, scattered brewing and poor
nasal-feeding liquidity. These technical
problems have become obstacles for FMSP
developments in China. Furthermore, as
FMSP does not provide single physiological
function with clear direction, it is also difficult
to evaluate during the clinical trial stage.
Therefore, clinic should be coordinated with
scientific developments.
26 · http://www.herbridge.com
http://www.herbridge.com · 27Asiaceutical Insights / 10th Issue 2017
Yunnan Aims to Create a “Healthcare Products Kingdom”
Recently, Yunnan Province made a three-year action plan on the
development of Yunnan’s biological medicine and comprehensive health industry,
aiming to reach a prime operating revenue of around RMB380 billion as of 2020,
of which about RMB100 billion is to be realized in the manufacturing sector.
Yunnan will encourage the construction of a batch of R&D centers
specialized in healthcare food, domestic cosmetics for special purposes, etc.,
develop a series of healthcare food and domestic special-purpose cosmetics
and lay emphasis on R&D and production of a number of food with special
formula for medical purposes by taking the common varieties (such as pseudo-
ginseng, gastrodia elata, erigeron breviscapus, dendrobium nobile, Yunnan Paris
polyphylla, etc.) and the biological resources with Yunnan’s characteristics (such
as haematococcus pluvialis, Lepidium meyenii, horseradish tree, walnut, tea leaf,
flowers and plants, konjak, blueberry, etc.) as the raw materials, establish a batch
of brand-name products with Yunnan’s characteristics reaching a sales revenue
of over RMB1 billion, and promote health products of Yunnan to become the key
products spreading in South Asia and Southeast Asia, so as to build a good image
of “a Kingdom of Healthcare Products” for Yunnan.
Build a Raw Material Base of Natural Medicine and Health Products
In the next 5 years, Yunnan will make
vigorous efforts in promoting the construction
of the premium raw material base of natural
medicine and health products, lay emphasis
on improving quality and increase efficiency
of the standardized planting (cultivation) base
of Chinese herbal medicines, and strive to
develop new resources and medicinal varieties
in short supply, so as to build Yunnan into
a top raw material of natural medicine and
health products in China. Give prominence
to the advantages and characteristics, build
the “hometown of Yunnan medicine”, attach
importance to the research on seed source
http://www.herbridge.com · 27Asiaceutical Insights / 10th Issue 2017
28 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Beverage Companies Step on the “Healthy” Route, Wahaha & Master Kong Taking the Lead
and construct a base of improved varieties,
foster the development of leading enterprises,
upgrade the raw material bases, focus on
promoting the large-scale development of
five traditional Chinese medicine common
varieties including pseudo-ginseng, erigeron
breviscapus, Yunnan Paris polyphylla,
dendrobium nobile and gastrodia elata,
develop varieties with medicine and food
dual purpose, and construct a comprehensive
park of traditional Chinese medicine. As of
2020, maintain about 8 million mu of planting
area and realize a prime operating revenue of
around RMB50 billion.
Construct the R&D and production base
of biological medicine and comprehensive
health products at a faster pace, give high
priority to the development of traditional
Chinese medicine (national herbal medicine),
give strong backing to the enterprises such
as Yuannan Baiyao, KPC Pharmaceuticals
and Longjin Pharmaceutical, build the
Kunming High-Tech Industrial Development
Zone into the largest R&D and production
base of medicine and healthcare products
of Yunnan Province, and construct a R&D
center of national herbal medicine focusing
on the medicine of the Yi, Dai and Tibetan
nationality. Make the existing biotechnological
pharmaceutical enterprises bigger and
stronger, and energetically carry out the R&D
and production of new biological vaccines,
antibody drugs, stem cell-based medicinal
products, biological detection reagent and
blood products as well as new products of
other protide, polypeptide and nucleic acid-
based drugs.
Recently, enterprises such as Coca Cola, Master Kong (Tingyi (Cayman
Islands) Holding Corporation) and Wahaha act vigorously in the area of “being
healthy and nutritious”. The functional beverage market in China is still
unsaturated, and comprehensive health has become the breakthrough point of
these enterprises.
Master Kong Makes Efforts in Developing Instant Nutritious Dairy Products
On February 10, Tingyi (Cayman Islands) Holding Corporation announced
that, Master Kong Beverage Investment (China) Co., Ltd. (hereinafter referred to
as “Master Kong Beverage”) has signed the cooperative agreement with Shanghai
AB Food & Beverages Ltd. (hereinafter referred to as “AB Food”) recently, and
http://www.herbridge.com · 29Asiaceutical Insights / 10th Issue 2017
that Master Kong Beverage acquired the
authorization of exclusively producing
and selling the Ovaltine instant malt
nutritious dairy products of AB Food
in the market of mainland China since
May 1 of this year. It is known that
Ovaltine is the “national nutritious
drink” in Switzerland, and the instant
malt nutritious dairy products produced
under the cooperation of AB Food and
Master Kong Beverage is one of the key
production lines of Ovaltine developing
quickly. The milk beverages developed
th i s t ime inc lude on ly Weiquan
lactobacillus beverage which is almost a
relative blank field in China.
Wahaha Promotes Enzyme Drinks
Wahaha launched the first enzyme
drink in China branded “Qingchang
Jiaozhu” (Master of Enzyme) in August
last year, and launched the “Jiaosu”
enzyme drink for females paying
attention to health and pursuing beauty
and a slim figure. Wahaha’s Jiaosu
is positioned as a “fruit & vegetable
enzyme” drink aiming to promote the
digestion function and lighten the burden
of human body, and is currently being
sold in the Micro-shop market by means
of FCL sales at a price of RMB5 /bottle.
In addition, Coca-Cola announced that
it will launch a “healthcare beverage”,
“Coca-Cola plus”, and this beverage
would be put on sale in Japan on March
27 with a standard of 470ml/ bottle and
at a price of JPY158 yen (approximately
RMB9.6). As introduced by Coca-
Cola, the fiber contained in Coca-Cola
plus would contribute to reducing the
absorption of fat, and help to control
the triglyceride level at meals so as
to decrease the risk of suffering from
cardiovascular disease.
Being Healthy and Nutritious Became the Main Trend of the Beverage Industry
Nowadays, there is an increasing
requirement of consumers for natural
and healthy products. Taking vegetable
protein drinks as the example, the
market size of China’s vegetable protein
drinks will reach about RMB73.3
billion by the year 2018, although it
was only RMB25.329 billion in 2013.
“In the future, exploring and satisfying
consumers’ individualized and socialized
requirements and developing their
drinking habits and consciousness will
be the important ways for enterprises
to pursue new profit growth.” Deputy
Secretary-General of China Association
for Quality (CAQ) Li Gaoshuai said.
In past two years, healthy functional
beverage has been growing like a
raging fire in the China market which
attracted numerous large enterprises. At
present, the whole functional beverage
market is not fully saturated, and many
enterprises reached their development
ceilings and thus transferred to the
comprehensive health industry. In the
future, comprehensive health industry
will not merely refer to beverages, but
also become the focus of the entire
fast-moving consumer goods (FMCG)
industry.
30 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
China Pharmaceutical Enterprises Transform to Healthcare Products Manufacturing
China pharmaceutical enterprises are
struggling to survive in the competition and
their market space are generally close to the
development ceilings, whereas nutritious
healthcare food still have great development
potentials. Therefore, pharmaceutical
enterprises have widely given attention to
and started to enter the market of healthcare
products.
China has over 200 A-share listed pharmaceutical enterprises and there are
increasing pharmaceutical enterprises setting foot in the field of healthcare products
in recent years. For example, Kangmei Pharmaceutical Co., Ltd. (600518.SH)
announced in May 2015 that it would acquire 74% stock rights of Shenzhen Mckin
Industry Co., Ltd. at the cost of RMB82.73 million, so as to enrich its varieties of
healthcare products and expand its market of terminal consumer goods by means of
integrating Mckin’s products and marketing channels.
Besides, many listed companies have separately disclosed their performance
in the field of healthcare products.
Performance of Partial Listed Pharmaceutical Enterprises in the First Half of 2016
Company Stock code Change of operating revenue
Change of net profit
Relevant business of healthcare products and proportion
Baiyun Mountain 600332 3.60% 8.89% Comprehensive health 43.30%
Kingworld Medicines 01110HK 13.75% 41.20% Healthcare products 18.85%
JZJT 600750 -33.95% 39.29% Healthcare food and others 12.63%
Zhejiang Medicine 600216 23.16% 46.78% Human nutritional supplements 12.41%
Tianmushan Pharmaceutical 600671 17.64% -34.12% Healthcare products 8.03%
Kangmei Pharmaceutical 600518 23.59% 22.91% Healthcare food 4.46%
Jointown Pharmaceutical 600998 24.66% 24.35% Food, healthcare products and
cosmetics 4.43%
Harbin Pharmaceutical 600664 -22.17% 2.09% Healthcare products 4.05%
Joincare 600380 17.50% -4.71% Healthcare products 2.95%
North China Pharmaceutical 600812 -12.00% 24.43% Vitamin and nutritious healthcare
products 2.89%
Neptunus Group 000078 17.86% 44.05% Healthcare products and food 2.84%
Renmintongtai Pharmaceutical 600829 -6.28% 27.99% Healthcare products 0.65%
http://www.herbridge.com · 31Asiaceutical Insights / 10th Issue 2017
Jingdong has once again bagged two Australian brands: targeting health care and meat products!
In August 2015, Jingdong established
strategic cooperation with two major
Australian brands, i.e. Blackmores and
Sanger. As a result, Jingdong was in a
position to provide Chinese consumers
Australian vitamins, dietary supplements
and meat pro.
Strategic cooperation agreement signed
between Jingdong and Blackmores
A s t h e n u m b e r o n e d i e t a r y
supplement brand in Australia with a
history of 85 years, Blackmores settled
in Jingdong's global platform in July
2015, and set up a unified Global flagship
store for Chinese consumers. At present,
Blackmores's evening primrose oil has
ranked first on Jingdong platform among
evening primrose oil products.
taste and flavor. In addition, Sanger will
also release new products on Jingdong’s
global purchase platform, including four
major categories, i.e. rib eye, chuck
tender, beef tendon and ribs.
S i n c e 2 0 1 6 , J i n g d o n g h a s
successively put online its Australian
pavilion, French pavilion, South Korea
pavilion, Japanese pavilion and U.S.
pavilion. On the launching ceremony of
Jingdong U.S. pavilion held in New York,
U.S.A., Liu Qiangdong, CEO of Jingdong
Group talked about the development
direction and goal of global purchase
business. In his opinion, the ultimate goal
of global purchase is that Chinese people
will be no longer rushing to buy at the
Fifth Avenue, Madison Square and other
places. Instead, they can buy these things
on Jingdong’s global purchase platform.
In addition, Liu Qiangdong also revealed
that there have already more than 1
million product varieties on Jingdong’s
global purchase platform.
Strategic cooperation agreement
signed between Jingdong and Sanger
As an Australian meat-exporter
founded in 1973, Sanger’s market has
expanded to more than 40 countries and
regions, covering the full range of retail
products such as beef, mutton, pork,
poultry, etc.
As disclosed by Jingdong side, the
strategic cooperation between Jingdong
and Sanger will lead to the selection of
traceable high quality meat products
closer to the source for China consumers,
and the introduction of Australia original
packaging materials, without any sub-
packaging and processing stages, so as to
ensure that merchandises have original
32 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Mannatech established cross-border E-commerce platform in China
Manna tech (MATTEL Dai ly
Health Care Products Co., Ltd.), a global
health solutions provider, announced
the establishment of cross-border
E-commerce platform (MeiTaiChina.com)
in mainland China.
The platform is about to sell
nutrition, health care and other related
products to Chinese consumers through
the adoption of direct-sales model.
Currently, two local modes of payment
Chinese mainland market, Mannatech has
adopted the inviter-awarding mechanism,
i.e. registered user of Mannatech can be
correspondingly rewarded as long as he/
she has invited another user to buy at least
one commodity at the site.
It is reported that Mannatech has
developed 26 markets in the past nearly
20 years. It is indicated in its official
website that Mannatech has entered 25
countries and regions, including China.
have been enabled, i.e. Alipay and
WeChat payment.
Screenshot taken from the official
website of Mannatech China mainland
In order to rapidly expand the
BigStylist, an India beauty care O2O platform, plans to collect $400 million through financing
BigStylist, an India beauty care O2O
platform, plans to collect $400 million
(about RMB 27.6 million) in a new round
of financing and these funds will be used
for the research and development of own-
brand beauty products for this platform.
It is reported in the Hindu Business Line
that the estimated value of BigStylist is
expected to reach 1.5 billion rupees (about
RMB 150 million) after the closure of this
round of financing.
BigStylist was founded in 2015, and
the platform services are currently only
opened to Mumbai and Pune, India. The
In the future, BigStylist will launch
new service items, beauty brands and
some health care products. Furthermore,
the market will also be expanded to
Hyderabad, Ahmedabad and Delhi.
Up to now, the company received
$2 million (about RMB 13.80 million)
from the seed round and Pre-A round of
financing. Since its inception, BigStylist
has received 50 million rupees (about
RMB 5.115 million) of revenues, and it is
expected that the revenues will reach 4.5
billion rupees (about RMB 460 million)
in the next five years.
door-to-door service coverage includes
waxing, facial care, manicure, foot care,
massage, bride makeup, hair coloring,
haircut and so on. The platform provides
three payment methods, i.e. cash payment,
India payment platforms of Paytm and
PayUMoney.
Screenshot taken from the official
website of BigStylist
http://www.herbridge.com · 33Asiaceutical Insights / 10th Issue 2017
Marriage of Global and Jamieson promotes a younger health care market?
VIPSHOP holds hands with Blackmores
Jamieson, a Canadian health care
brand recently goes online in Global
for the purpose of expanding mobile
e-commerce market in Chinese mainland.
According to reports, based on the
market characteristics that customer base
of mobile terminal tends to be younger,
Jamieson will make use of the advantage
of Global, expand the e-commerce
market in mainland China through the
“mobile social + convergence marketing”
mode, and provide domestic consumers
wi th nut r i t ional hea l th products
originating in Canada, including grape
VIPSHOP overseas special signed
a strategic cooperation agreement
in Guangzhouwith Blackmores, an
Australian dietary supplement brand. For
this cooperation with VIPSHOP, Zhang
Zujun, general manager from Blackmores,
expresses that VIPSHOP is China’s
first special offer e-commerce platform
in which “refined selection+ shopping
guide” model is adopted. It is hoped that
based e-commerce has formed the word
of mouth marketing via the integration of
friend circle, and the communities sharing
the common consumption characteristics
and habits have become the mainstream
of marketing. Under this circumstance,
Global can ultimately realize the double
promotion of brand public praise and
market sales through the utilization of its
own mobile social features, provision of
assistance to Jamieson in the promotion
of mutual trust between consumers and
brand, and elevation of user stickiness.
platform in South Korea. Subsequently,
VIPSHOP overseas special signed
cooperative agreement with the U. S. &
Foreign Commercial Service (FCS), held
investment fairs in Australia, and signed
cooperative agreement with UK Trade
& Investment (UKTI), with the purpose
of introducing commodities from the
U.S.A. Australia, UK and other places.
seed concentrated compound tablets,
orange-flavored Vitamin C chewable
tablets, vitamin B group B50 and other
hot products.
According to the person in charge
of Jamieson, the socialnomics represents
an important direction of future business
development, and everyone can be not
only a brand consumer, but also a brand
communicator. These characteristics are
consistent with Jamieson’s demands for
advancing towards the mobile terminal.
As indicated by Global, from the
beginning of 2016, social community-
this cooperation can provide Blackmores
products for 100 million members of
VIPSHOP.
Since its overseas special has gone
online in last September, VIPSHOP
has successively signed cooperative
a g r e e m e n t s w i t h K o r e a T r a d e
Promotion Corporation (KOTRA), a
government sector of South Korea, as
well as CAFE24, a famous e-commerce
34 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Beijing Consumers Association: cross-border E-commerce has become a severely-afflicted area for sales of counterfeit health care food products
As indicated by the statistical
data of complaints handled by China
Consumers Association, complaints of
health care food reached 2389 cases, with
quality problems (903 cases) and false
propaganda (436 cases) accounting for the
largest proportion. In addition, complaints
about medical equipment, health care
products, traditional Chinese medicine
and Chinese patent medicines also hold a
higher proportion.
Beijing
Failure to retain an operative
receipts may cause difficult problem for
handling
In Beijing area, as indicated in
the statistics of complaints about food
products during the first half of last
year released by Beijing Consumer
Association, complaints about health
care products ranked first in the food
products-related complaints, accounting
for 9.15% of the total complaints about
food products, and the complaints
about false propaganda accounted for
26.09% of health care product-related
complaints. In this category of complaint,
most elderly consumers are deceived.
By grasping the mentality of paying
attention to health among the elderly, in
the name of health lectures, compulsory
medical examination, guarantee to cure all
represented by online shopping and TV
shopping has also become a field where
consumer complaints are prone to occur.
In 2015, National Consumers Association
accepted 20083 cases of complaints
about remote shopping, accounting for
69.86% of sales and service complaints.
Cross-border online shopping has
become a severely-afflicted area of online
shopping complaints, and proliferation
of counterfeit commodities is one of the
main reasons. As a result, some well-
known health care food manufacturers
and consumers are deeply hurt.
According to Amway (China),
it previously entrusted a third party
inspection and accreditation agency
to carry out sampling and testing of
Amway products sold on China’s
largest e-commerce platform, and the
results show that 46% are counterfeit
products. According to the briefing,
in June 2015, Amway worked with
the Public Security Department from,
Chaonan Dis t r ic t , Shantou Ci ty,
Guangdong Province and cracked
down a den where counterfeit Amway
protein powder are packaged and
distributed. There are 416 finished
products of counterfeit Amway protein
powder are sized at the site, together
with a batch of semi-finished products
and packaging materials. The total
diseases other exaggerated propaganda,
and the utilization of discount, prizes,
gifts and other means, some unscrupulous
operators seize the opportunity to
ballyhoo, peddle health care products and
even pass off ordinary food as health care
food products.
As pointed out by Beijing Consumer
Association, although the complaints and
queries about health care products remain
high, yet there are few cases truly accepted
due to the unclear subject of defendant,
failure to retain operative receipts and other
evidences. Even if cases are accepted, yet it
is very difficult to request a full refund, let
alone compensations, due to the difficulty
in determining the responsibility for the
quality of health care products which tend
to be ineffective, yet have no obvious
harmful effect. By taking the complaints
about exaggerated propaganda and
advertisements in the marketing process
of health care products, it is difficult for
consumers to provide the evidences of
exaggerated advertising, since word of
mouth recommendation and other means
are mostly adopted by merchants.
Nationwide
Counterfeit articles of health
care food products are sold via remote
shopping platform
It is noteworthy that remote shopping
http://www.herbridge.com · 35Asiaceutical Insights / 10th Issue 2017
Jamieson health care products settled in Vipshop
Vipshop Global under VIP.com
established strategic cooperation with
Jamieson, a brand of Canadian health care
product, and became its first cross-border
e-commerce strategic partner in china.
Vipshop Global established cooperation
with Jamieson
From June 27, Jamieson products
launched the “Vitamin day” under the
T h e r e s p o n s i b l e o f f i c e r o f
Vipshop Global comments like this,
“As the world’s largest special offer
e-commerce supplier, Vipshop has an
excellent platform resources and high
quality membership. The initiative of
reintroducing well-known Canadian brand
nutrition and health care products with
great reputation will continuously bring
about unexpected shopping experience to
Chinese consumers.”
Jamieson
Vipshop Global channel and adopted
the mode of direct distribution from the
bonded warehouse. According to reports,
founded in 1922, Jamieson is a well-
known Canadian food manufacturer
engaged in the production of vitamins,
minerals, herbs and other dietary
supplements and nutrit ional food
products. Moreover, it is also one of the
world’s three major brands of nutrition
and health care products. Jamieson’s
cross border e-commerce sales channels
comprise Jamieson’s overseas flagship
store, Jingdong global purchase under
Tmall Global (bonded warehouse model
is adopted in the former one, while direct
mail in the latter one).
value involved in this case amounted
to RMB 2.22 million.
[Case]
In last May, 77-year-old aunt Zhao
heard that health care lectures would be held
by the neighborhood organization, and there
would be five famous hospital experts who
provide volunteer medical consultation. For
this reason, she came to a grand hotel to
attend the lectures on schedule. “Experts”
fervently took her blood pressure, pulse,
wrote out a prescription, and also guarantee
the curative effect. The said medical staffs
enthusiastically sent “Medicine” to her
home and charged RMB 2700 before
they left. When she opened the package,
finding that the so called “Medicine” was
merely soft capsule health care products
produced by a biotechnology company.
Unexpectedly, allergy symptoms appeared
in her body after she took such medicine.
Afterwards, she was diagnosed as a rash in
the hospital. When aunt Zhao argued with
the salesmen who sold her this medicine,
that gay persuaded her to go on taking such
medicine. Aunt Zhao was so angry that she
become out of breath. However, such gay
refused to receive phone calls from aunt
Zhao. Finally, thanks to the mediation of
consumer association, the operator called
back the remaining health care products,
and refunded RMB 2250.
36 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
CFDA released Detailed Regulations for Health Food Products Registration
In January 2017, the State Food and
Drug Administration (SFDA) issued the
Directory for Raw Materials of Health
Care Food Products (1) and the Directory
for Allowing the Health Care Functions of
Health Care Food Products (1), which laid
the foundation for the implementation of
health food product registration system. In
February 7, SFDA also officially released
Detailed Regulations for Health Food
Products Registration (exposure draft),
including 8 main items and 22 pages. It
provides detailed description of registration
Registration Procedures (as shown in the figure)
work in production enterprises.
These detailed regulations for touch upon several aspects of registration work, including
scope of application, form of registration, contents of registration materials, registration
requirements for domestic health care products, registration requirements for imported health
care products, changes in registration, registration cancellation, information disclosure and so on.
Subject of registration
The production and import of health care food products should be produced in
accordance with laws. Among them, the application for registration of domestic health care
products shall be submitted to the Food and Drug Administration at all provinces, autonomous
regions and municipalities directly under the Central Government. The on-site application
for registration of imported health care products shall be submitted to the administrative
acceptance service department of SFDA.
not be used by the same enterprise. The same name shall not be used in the registration
of health care food products that correspond to different formulas. The same formula
refers to the scenario in which the categories and amount of usage of raw materials and
supplementary materials are all consistent. The same name refers to the scenario in which
product trade name, common name and attribute name are all consistent.
This provision is a great impact on the industry, which means that many OEM
health care product brands will receive a blow. In the health care food industry, OEM
production is very common. In another word, one health care food product with one
Requirements for Registration
Materials
There are five core requirements
listed in these detailed regulations.
Among them, it is stressed in the last
provision that health care food products
with different names that correspond
to the same formula registration shall
http://www.herbridge.com · 37Asiaceutical Insights / 10th Issue 2017
registered number of approval may be
packaged into products with multiple
brands and even dozens of brands after
production and prior to sales.
On one hand, this reduced the
difficulty of entry of health care food
brands into the market. On the other hand,
the market order was disturbed by many
non-standard enterprises through the
utilization of OEM production.
Registration Materials for Domestic
Health Care Food Products
Health care food product specification
(template)
Health care food registration
XXX brand XXX(Chinese name)
Raw material:
Supplementary material:
Functional ingredients or signature
ingredient and content:
Commended user:
Commended user:
Healthcare function:
Recommended dosage & edible
method:
Specification:
Storage method:
Quality guarantee period:
Attention:
1. About the formula: The manufacturer
should submit the product formula sheet
automatically generated from the health care
food registration management information
system. The usage amount of raw materials
and supplementary materials refer to the
usage amount required for the production of
1000 minimum preparation units.
The vitamins, minerals and other
nutrients supplemented in health care
food products shall be arranged as per
the sequence of nutrients specified in
Directory for Raw Materials of Health
Care Food Products. In case several kinds
of chemical compounds are used in the
same kind of nutrient, it is required to
collate as per the size of usage amount.
The raw materials for other products shall
be sequenced as per the Directory for Raw
Materials of Health Care Food Products.
2. About the health care function:
For products complying with the
Directory for Raw Materials of Health
Care Food Products, health care function
shall be marked according to relevant
provisions. Nutritional supplements
should list out all vitamins or minerals to
be supplemented, with such representation
as “XX supplemented”. For products
containing three or more vitamins or
minerals, it is required to represent
like this “Multivitamins or minerals
supplemented”. However, it is not allowed
to represent in the form of “one or several
kinds of raw materials+ multivitamins
or minerals supplemented”. Health care
food products containing three and more
vitamin B groups can be represented as
“Vitamin B group supplemented”.
3. About the denomination: The
following names can be chosen as
common names for nutrient supplement
products:
(1) Names of all nutrients shall be
listed in accordance with the arrangement
sequences specified in the Directory for Raw
Materials of Health Care Food Products. For
health care food products containing three or
less nutrients, names of all nutrients shall be
used as common names.
(2) For nutrients supplementation
containing three and more Vitamins or
minerals, common names can be called as
“Multivitamins or minerals”. However, it
is not allowed to denominate in the form
of “one or several kinds of raw materials+
multivitamins or minerals “.
(3) For nutrients supplementation
containing three and more B vitamins
(vitamin B1, vitamin B2, vitamin
B6, vitamin B12, niacin, pantothenic
acid, folic acid, etc.), it is required to
denominate them as “Nicotinic acid
Vitamins”.
Regis trat ion Mater ia l s for
Imported Health Care Food Products
In addition to the submission of
relevant materials required for domestic
products, it is also required to submit
the following documents, including
qualification documents of the registration
applicant (i.e. overseas manufacturer
of health care food products) and the
documentary evidence of health care food
products sold in the market for more than
one year. Such qualification documents
and documentary evidence shall be issued
by the competent government authorities
or legal services agency of the country
(region) where products are produced.
Reports to be submitted also include the
safety report on products sold abroad
and crowd consumption, or relevant
original copies of technical regulations or
standards for health care food products
formulated by the country (region) or
international organization where products
are produced.
38 · http://www.herbridge.com 10th Issue 2017 / Asiaceutical Insights
Recommended